AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2575981
Drug: metoprolol 100mg
RxNorm normalized name: HCTZ 25/METOPROLOL 100MG TAB
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol 100mg twice a day
Trial: 2575981
Drug: nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine retard 20mg twice a day
Trial: 25689244
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, then 75 mg/day)
Trial: 20538132
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of furosemide (mean dose 162 ± 48 mg/24 hours)
Trial: 20538132
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of furosemide (mean dose 162 ± 52 mg/24 hours)
Trial: 17009113
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg/kg) with midazolam (0.05 mg/kg)
Trial: 17009113
Drug: Tramadol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1 mg/kg) with midazolam (0.05 mg/kg)
Trial: 17009113
Drug: Tramadol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (2 mg/kg) with midazolam (0.05 mg/kg)
Trial: 12699522
Drug: Initial diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial diabetes training for the emergency team and standardized protocol for prehospital emergency therapy of severe hypoglycaemia (SH)
Trial: 12699522
Drug: Education of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education of insulin-treated patients about their diabetes
Trial: 12699522
Drug: Mandatory additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory additional glucose infusions and hospitalization for sulfonylurea-induced SH
Trial: 8928243
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg daily for 24 months
Trial: 6430439
Drug: Determination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determination of renal beta 2 microglobulin excretion
Trial: 6430439
Drug: Immunofluorescence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunofluorescence of antibody coated bacteria
Trial: 6430439
Drug: Scintiphotography with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scintiphotography with 67Ga and determination of renal beta 2 microglobulin excretion
Trial: 6430439
Drug: Excretion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excretion of beta 2 microglobulin and uptake of 67Ga in patients with lower urinary tract infections
Trial: 31099333
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day magnesium oxide
Trial: 27067676
Drug: Eight weekly
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight weekly one hour meditation‐focused mind/body classes teaching concentration and insight meditation skills along with mind/body exercises.
Trial: 27067676
Drug: Eight weekly
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight weekly one hour meditation‐focused mind/body classes.
Trial: 19909984
Drug: De Vega
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De Vega + pericardial patch augmentation
Trial: 19909984
Drug: Ring annuloplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ring annuloplasty + pericardial patch augmentation
Trial: 1975333
Drug: M37 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M37 vaccine (1 x 10(4) pfu)
Trial: 1975333
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (1 x 10(4) pfu each of serotype 3 RRV and human rotavirus‐RRV reassortants of serotypes 1, 2, and 4)
Trial: 1975333
Drug: Balanced quadrivalent
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced quadrivalent vaccine (1 x 10(4) pfu of serotype 1 and 3 components but 5 x 10(4) pfu of serotype 2 and 4 components)
Trial: 6791212
Drug: 0.50 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 ml/kg alcohol
Trial: 6791212
Drug: 1.0 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml/kg alcohol
Trial: 6791212
Drug: 0.025 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 ml/kg alcohol
Trial: 26721142
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with acupoint embedding therapy
Trial: 21169640
Drug: Phenobarbital (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (40 mg/kg)
Trial: 2959426
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals)
Trial: 2959426
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 to 10 mg b.i.d.)
Trial: 29635693
Drug: CO2 fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 fractional laser treatment (one treatment each month) with topical 0.1% tacrolimus cream
Trial: 29635693
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% tacrolimus cream
Trial: 26541905
Drug: Rapid-onset antiplatelet
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-onset antiplatelet therapy (prasugrel or glycoprotein IIb-IIIa) in the prehospital setting
Trial: 25070482
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral product of pioglitazone hydrochloride with increased hydroxypropyl cellulose (HPC)
Trial: 25070482
Drug: Reference listed
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference listed drug (RLD) pioglitazone hydrochloride
Trial: 20670726
Drug: Verapamil SR-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR-based treatment
Trial: 20670726
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment strategies (Verapamil SR and Atenolol)
Trial: 12744767
Drug: Warming therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming therapy using a Warm Up device (n = 8)
Trial: 11171790
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of vitamin C
Trial: 11171790
Drug: Sequential infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential infusions of dobutamine (Dob, Dob-2) without vitamin C
Trial: 9394695
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with metronidazole for E. histolytica
Trial: 3445589
Drug: Live combined
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live combined mumps-measles vaccine (MMV)
Trial: 9106373
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) with ERT
Trial: 9106373
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) without ERT
Trial: 21226937
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive therapy (CT) while tapering antidepressants (AD)
Trial: 21226937
Drug: Maintenance antidepressants
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance antidepressants (AD)
Trial: 21226937
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of brief cognitive therapy (CT) with maintenance antidepressants (AD)
Trial: 12739706
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily (o.d.)
Trial: 12739706
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg twice daily (b.i.d.)
Trial: 10561627
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 microg at 4-hour intervals for a maximum of 6 doses)
Trial: 10561627
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter plus oxytocin (maximum dose of 36 mU/min)
Trial: 8901793
Drug: Follow-up for
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up for calcium tablet group
Trial: 1667474
Drug: Customary oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customary oral hygiene procedures
Trial: 6351894
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir ointment, applied five times a day for 5 days
Trial: 22845494
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) tapentadol 50 mg
Trial: 22845494
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) tapentadol 75 mg
Trial: 22845494
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) tapentadol (unspecified dosage)
Trial: 17533178
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (50 microg per nostril per day) for 40 days
Trial: 17533178
Drug: Topical intranasal
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intranasal steroid treatment on alternate days for the first 2 weeks per month (group A1)
Trial: 17533178
Drug: Continued daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued daily mometasone treatment for the first 2 weeks per month (group A2)
Trial: 17533178
Drug: Mometasone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone treatment
Trial: 15621710
Drug: Vegetal formulation
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetal formulation of superoxide dismutase (SOD)
Trial: 7530473
Drug: L-NMMA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (2 mumol min-1) with bradykinin (100 pmol min-1)
Trial: 7530473
Drug: L-NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (4 mumol min-1) with bradykinin (100 pmol min-1)
Trial: 7530473
Drug: L-NMMA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (2 mumol min-1) with substance P (1 pmol min-1)
Trial: 7530473
Drug: L-NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (4 mumol min-1) with substance P (1 pmol min-1)
Trial: 3292363
Drug: Azathioprine at
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine at a dose of 2 mg per kg
Trial: 3292363
Drug: Conventional combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combination regimen of azathioprine (1 mg per kg) with prednisolone
Trial: 31682162
Drug: Acumapimod 75
RxNorm normalized name: Acumapimod
DrugBank: Acumapimod (DB15448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acumapimod 75 mg repeated single-dose on Days 1 and 6
Trial: 31682162
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 40 mg (10 days)
Trial: 31682162
Drug: Acumapimod 20
RxNorm normalized name: Acumapimod
DrugBank: Acumapimod (DB15448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acumapimod 20 mg single-dose
Trial: 28903510
Drug: RAL (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL (400 mg twice daily)
Trial: 21240871
Drug: ARB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB group (valsartan 40-80 mg daily for 6 months)
Trial: 19406981
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg plus isoniazid placebo
Trial: 19406981
Drug: Isoniazid 300
RxNorm normalized name: isoniazid 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 300 mg plus moxifloxacin placebo
Trial: 10829320
Drug: Preoperative visualization
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative visualization therapy (Group A)
Trial: 10829320
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative therapy (Group B)
Trial: 8891847
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (interferon alone and combined therapy)
Trial: 1381022
Drug: Isradipine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 1.25 mg twice daily (b.i.d.)
Trial: 28089180
Drug: PL2200 (modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL2200 (modified-release lipid-based aspirin, 325 mg)
Trial: 28089180
Drug: Delayed-release enteric-coated
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed-release enteric-coated (EC) aspirin (325 mg)
Trial: 21199966
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (BLT) for 3 weeks, 1-hour early-morning exposure to pale blue light at approximately 7500 lux
Trial: 21199966
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (BLT)
Trial: 19595483
Drug: Lansoprazole orally
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole orally disintegrating tablets (30mg for 3 days)
Trial: 19595483
Drug: Lansoprazole capsules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole capsules (30mg for 3 days)
Trial: 19595483
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to pay for orally disintegrating tablets
Trial: 26170014
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron intervention
Trial: 17999080
Drug: 200‐mg/day doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mg/day doxycycline for 4‐6 weeks
Trial: 12765924
Drug: Aerochamber (AC)
RxNorm normalized name: AEROCHAMBER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerochamber (AC) with 200 micro g budesonide twice daily
Trial: 12765924
Drug: Nebuchamber (NC)
RxNorm normalized name: codeine phosphate / pseudoephedrine hydrochloride / triprolidine hydrochloride Oral Solution [Poly Hist NC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuchamber (NC) with 200 micro g budesonide twice daily
Trial: 9124243
Drug: Topical carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical carteolol hydrochloride 1%
Trial: 8267038
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus low-dose aspirin (n = 12)
Trial: 8267038
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (n = 22)
Trial: 31397133
Drug: Ultrasound-guided intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intrathecal injection (control group)
Trial: 27862108
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy (CBT4BN)
Trial: 27862108
Drug: Traditional face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional face-to-face group cognitive-behavioral therapy (CBTF2F)
Trial: 19328598
Drug: Practidose individualised
RxNorm normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practidose individualised dispensing and dosing pillbox system
Trial: 16603337
Drug: Parent-implemented Reciprocal
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-implemented Reciprocal Imitation Training (RIT), implemented twice a week for 10 weeks.
Trial: 16603337
Drug: Generalization assessed
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalization assessed in families' homes at the end of treatment and a 1-month follow-up.
Trial: 16827430
Drug: Hypervolemic hypertensive
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypervolemic hypertensive hemodilution (3H-therapy)
Trial: 16827430
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no 3H-therapy)
Trial: 12662378
Drug: Lafutidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine (20 mg twice daily)
Trial: 12662378
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg twice daily)
Trial: 1706207
Drug: Alkylating agents
RxNorm normalized name: ALKYLATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating agents or intensive chemotherapy
Trial: 6124236
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (desensitization followed by Masters and Johnson)
Trial: 31771991
Drug: Mobile low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mobile low-dose CT screening unit
Trial: 25741580
Drug: Probiotic-containing lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-containing lozenges
Trial: 23446957
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg
Trial: 18037544
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg vaccine
Trial: 18037544
Drug: 5 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg vaccine
Trial: 18037544
Drug: 2.5 microg
RxNorm normalized name: Digoxin 62.5 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 microg vaccine
Trial: 18037544
Drug: Four low
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four low doses of 2.5 microg
Trial: 18037544
Drug: Four low
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four low doses of 5 microg
Trial: 17172187
Drug: Rifaximin 200
RxNorm normalized name: rifAXIMin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 (2 cp bid for ten days in a month) followed by Bifidobacterium longum W11 (one granulated suspension for 6 days on alternate weeks)
Trial: 9206199
Drug: Anti-lipid A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-lipid A of LPS antibody (anti-LPS treatment group)
Trial: 1728077
Drug: Ranitidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (100 mg intravenously every 12 hours for 72 hours)
Trial: 6383045
Drug: Ritodrine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine, 120 mg daily (oral)
Trial: 6383045
Drug: Terbutaline, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline, 30 mg daily (oral)
Trial: 6383045
Drug: Terbutaline (oral)
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline (oral)
Trial: 6383045
Drug: Ritodrine (oral)
DrugBank: Ritodrine (DB00867)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritodrine (oral)
Trial: 6383045
Drug: Ritodrine (intravenous)
DrugBank: Ritodrine (DB00867)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritodrine (intravenous)
Trial: 6383045
Drug: Terbutaline (intravenous)
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline (intravenous)
Trial: 26930488
Drug: Therapist-Assisted Internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-Assisted Internet-delivered Cognitive Behavior Therapy (TA-ICBT)
Trial: 11181239
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy at a mean flow rate of 1.3 +/- 0.4 l/min
Trial: 11181239
Drug: Air administered
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air administered at the same flow rate